Zydus

Zydus receives USFDA approval for Methenamine Hippurate Tablets USP, 1 gram

Zydus gets USFDA final approval for Ketoconazole Shampoo, 2%

Zydus Lifesciences secures USFDA approval for Dasatinib Tablets

Zydus launches VaxiFlu-4, India’s latest flu vaccine for 2025

Zydus gets USFDA nod for Ibuprofen and Famotidine tablets

Zydus Lifesciences shares surge nearly 3% after US FDA issues no observations for Ambernath unit

Zydus and Beihai Biotech sign strategic agreement for BEIZRAY product for the US market

Zydus’ Topical manufacturing facility clears USFDA inspection with zero observations

Zydus signs exclusive agreement with Synthon for a novel 505(B)(2) oncology product for US market

Zydus gets USFDA approval for Phase II(b) trial of Usnoflast in ALS treatment

Zydus signs strategic agreement with CVS Caremark to add Zituvio , Zituvimet and ZituvimetTM to its template formulary

Zydus Life to divest 6.5% stake in Mylab Discovery Solutions for Rs 106 crore

Citi maintains its Sell call on Zydus, expressed concerns over Sterling Biotech deal

Zydus Lifesciences shares tumbled to a nearly two-month low on Monday, following the company's announcement of a 50% stake acquisition in Sterling Biotech Ltd. for Rs 550 crore.

Zydus receives final approval from the USFDA for its NDA Zituvimet TM XR extended release tablets

Zydus Lifesciences reports impressive 53.2% rise in Q2 net profit

Indian pharmaceutical company Zydus Lifesciences posted robust financial results for the July-September quarter of the fiscal year 2023-2024.